At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 398 enrolled
Drug / intervention
Moxifloxacin +3 moredrug
Likely dose
Moxifloxacin 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3B Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial To Evaluate The Efficacy and Safety Of Azithromycin SR (Microspheres Formulation) Versus Moxifloxacin For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB).
In Brief
A Phase 3 clinical trial evaluating Moxifloxacin Placebo, Moxifloxacin, and 2 other interventions for Chronic Bronchitis. Completed, enrolled 398 participants across 34 sites in 6 countries.
Detailed Summary
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Bronchitis
CountriesChina, Malaysia, Philippines, Singapore, Taiwan, Thailand
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2005
Enrollment StartFeb 2006
Primary CompletionAug 2008
TodayJul 2026
First PostedNov 16, 2005
Enrollment StartFeb 1, 2006
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 20.6 years ago
Interventions
Moxifloxacin Placeboother
1 capsule once daily for 5 days
Moxifloxacindrug
1 X 400mg capsule once daily for 5 days
Azithromycin SR Placeboother
single dose, oral.
Azithromycin SRdrug
single dose 2.0 g oral